Fundraising Foxルクサナバイオテク株式会社
3 known investors
Find your way into ルクサナバイオテク株式会社
Sign up to see every warm intro you have to ルクサナバイオテク株式会社
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ルクサナバイオテク株式会社 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Luxna Biotech develops nucleic acid medicines (oligonucleotide/antisense therapeutics) based on bridged/crosslinked modified nucleic acid chemistry originally developed at Osaka University. The company's licensed modifications aim to bind target mRNA more strongly, improve efficacy, reduce liver toxicity risk, and potentially alter tissue delivery of nucleic acid drugs.
Investors · 3
Frequently asked questions
- What does ルクサナバイオテク株式会社 do?
- Luxna Biotech develops nucleic acid medicines (oligonucleotide/antisense therapeutics) based on bridged/crosslinked modified nucleic acid chemistry originally developed at Osaka University. The company's licensed modifications aim to bind target mRNA more strongly, improve efficacy, reduce liver toxicity risk, and potentially alter tissue delivery of nucleic acid drugs.
- Who are ルクサナバイオテク株式会社's investors?
- ルクサナバイオテク株式会社's investors include Kobe University Capital, OSAKA University Venture Capital, TOHOKU University Venture Partners.